DEUTSCHES HERZZENTRUM BERLIN

Their core work

Deutsches Herzzentrum Berlin is one of Germany's leading specialized cardiac surgery hospitals, providing advanced clinical care and participating in the development of medical devices and surgical technologies for heart disease. In EU-funded research, they serve as a clinical validation site — testing new cardiac monitoring tools, surgical systems, and decision-support platforms on real patients. Their contribution centers on providing clinical expertise, patient cohorts, and real-world surgical environments where innovations in cardiac care can be rigorously evaluated.

What they specialise in

How they've shifted over time

DHZB's early H2020 work (2016) focused on computational decision support and health data infrastructure, as seen in EurValve and MH-MD. From 2018 onward, their projects shifted decisively toward hands-on surgical innovation and bedside monitoring — SAMBAfun brought accelerometer-based cardiac assessment to critical care, while SAFE-CAB targeted minimally invasive bypass surgery with laser technology. The trajectory shows a move from data and modeling toward physical devices and surgical systems tested in clinical settings.

DHZB is moving toward clinical validation of physical medical devices for cardiac surgery and critical care monitoring, making them a strong partner for medtech companies needing a hospital-based trial site.

How they like to work

DHZB participates exclusively as a partner, never as a coordinator — consistent with their role as a clinical end-user providing hospital expertise and patient access rather than managing research consortia. With 37 unique partners across 12 countries in just 4 projects, they operate in sizable, international consortia. This pattern suggests they are valued as a clinical validation site that technology developers and research groups actively recruit into their projects.

DHZB has collaborated with 37 distinct partners across 12 countries through 4 projects, indicating involvement in large, geographically diverse consortia. Their network spans the European medtech and clinical research ecosystem, with no apparent concentration in a single country cluster.

What sets them apart

DHZB offers something rare in EU consortia: direct access to a high-volume cardiac surgery center where medical devices and clinical decision tools can be tested with real patients in operating rooms and ICUs. Unlike university labs or research institutes, they bring immediate clinical relevance — their surgeons and cardiologists use the technologies being developed. For any consortium developing cardiac medtech, DHZB provides the clinical credibility and regulatory-grade trial environment that funding agencies want to see.

Highlights from their portfolio

• EurValve
  Largest single EC contribution to DHZB (EUR 427,148), focused on personalized heart valve disease decision support — combining clinical data with computational modeling.
• SAFE-CAB
  Targets a direct surgical application — laser-assisted minimally invasive coronary bypass — with clinical trial involvement, representing DHZB's clearest path to commercial medtech impact.
• SAMBAfun
  Develops a novel accelerometer-based system for real-time cardiac function monitoring in critical care patients after open-heart surgery — a bedside innovation with strong practical value.